ANDA 204843, held by Meitheal Pharmaceuticals. Dexmedetomidine Hydrochloride.
As of Nov 22, 2026, ANDA 204843 (Dexmedetomidine Hydrochloride), held by Meitheal Pharmaceuticals, was first approved by FDA on Jan 18, 2019, with 4 approved supplements and 0 published complete response letters.
Dexmedetomidine Injection is a alpha 2 -adrenergic receptor agonist indicated for: Sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting. Administer Dexmedetomidine Injection by continuous infusion not to exceed 24 hours. Sedation of non-intubated adult patients prior to and/or during surgical and other procedures. 1.1 Intensive Care Unit Sedation Dexmedetomidine Injection is indicated for sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting. Dexmedetomidine Injection should be administered by continuous infusion not to exceed 24 hours.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 18, 2019 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Dexmedetomidine HydrochlorideEQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) · injectable;injection | Dexmedetomidine Hydrochloride | Rx |
| Oct 22, 2026 | Supplement 8Labeling · Standard review | Approved | None posted |
| Oct 22, 2026 | Supplement 6Labeling · Standard review | Approved | None posted |
| Oct 22, 2026 | Supplement 4Labeling · Standard review | Approved | None posted |
| Mar 25, 2021 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jan 18, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters